Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00912301 · ClinicalTrials.gov registry record · Phase 2
Cheno Effect on Transit in Health and IBS-C
A Phase 2 study of Constipation-predominant Irritable Bowel Syndrome, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT00912301 is a Phase 2 study of Constipation-predominant Irritable Bowel Syndrome that has completed, run by Mayo Clinic. The registered enrollment target is 36 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00912301, a Phase 2 study of Constipation-predominant Irritable Bowel Syndrome, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
The study hypothesis is that the naturally occurring bile acid, chenodeoxycholic acid, induces acceleration of colonic transit in health and in patients with constipation-predominant Irritable Bowel Syndrome (IBS-C).
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Sodium chenodeoxycholate (NaCDC)
Study Locations (1)
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2009-04 |
| Est. Completion | 2009-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00912301
The ClinicalTrials.gov registry entry for NCT00912301 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Constipation-predominant Irritable Bowel Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00912301 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT00912301 about?
NCT00912301 is a clinical study titled "Cheno Effect on Transit in Health and IBS-C". The study hypothesis is that the naturally occurring bile acid, chenodeoxycholic acid, induces acceleration of colonic transit in health and in patients with constipation-predominant Irritable Bowel Syndrome (IBS-C).
What is the current status of trial NCT00912301?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2009-04. Estimated completion is 2009-12.
What conditions does trial NCT00912301 study?
This clinical trial studies the following conditions: Constipation-predominant Irritable Bowel Syndrome.
What interventions are being tested in trial NCT00912301?
The interventions under investigation include: Placebo (OTHER), Sodium chenodeoxycholate (NaCDC) (DRUG).
Who is sponsoring clinical trial NCT00912301?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00912301 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.